Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue

Information

  • Research Project
  • 9565679
  • ApplicationId
    9565679
  • Core Project Number
    R44NS082222
  • Full Project Number
    5R44NS082222-05
  • Serial Number
    082222
  • FOA Number
    PAR-14-209
  • Sub Project Id
  • Project Start Date
    1/15/2014 - 11 years ago
  • Project End Date
    8/31/2019 - 5 years ago
  • Program Officer Name
    FERTIG, STEPHANIE
  • Budget Start Date
    9/1/2018 - 6 years ago
  • Budget End Date
    8/31/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    05
  • Suffix
  • Award Notice Date
    8/13/2018 - 6 years ago
Organizations

Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue

Project Summary Montana Molecular is in the business of developing and marketing genetically encoded biosensors for academic research and drug discovery in living cells. Our biosensors provide robust detection of crucial second messenger signaling, including DAG, PIP2, cAMP and Ca2+ on both fluorescence microscopes and the large installed base of automated plate readers, with metrics that match or surpass those of traditional biochemical and luminescence based assays. We have an established customer base, with over 100 early adopters in academia and industry. Our customers and industry partners have indicated a growing need for assays capable of targeting specific populations of living neurons and for ?assay-ready? iPSC derived neuronal lines for use in academia and secondary drug screens. Genetically encoded assays for GPCR signaling, developed by Montana Molecular, fit seamlessly with these needs. They can be used for kinetic measurements in living cells, can be targeted to specific populations of cells in complex tissue, and have been independently validated on a wide variety of fluorescence microscopes and automated plate readers. To meet the needs of our customers and to penetrate the growing human iPSC market, we propose two specific aims. In Aim 1 we will engineer a new baculovirus vector that circumvents the payload limits and safety considerations of Lentivirus and AAV. In Aim 2, we will partner with iPSC developers in both academia and industry to create the first assay-ready iPSC derived neurons stably expressing biosensors for the detection of multiple facets of GPCR signaling.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R44
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    210309
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:210309\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MONTANA MOLECULAR, LLC
  • Organization Department
  • Organization DUNS
    145280157
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    597158250
  • Organization District
    UNITED STATES